Drawing based on the label description. No photo yet.
“Lisinopril and hydrochlorothiazide tablets USP,20 mg/12.5 mg are yellow, round tablets, imprinted with 'H151' on one side and plain on the other side”
H151 pill
Pill with imprint H151 is yellow, round, 8 mm and has been identified as Lisinopril/Hctz 20 mg / 12.5 mg. It is used for high blood pressure and quitting smoking. It is supplied by Direct_rx.
Lisinopril/Hctz 20 mg / 12.5 mg
- Imprint
- H151
- Strength
- Lisinopril 20 mg / Hydrochlorothiazide 12.5 mg
- Used for
- High blood pressure and quitting smoking
- Color
- Yellow
- Shape
- Round
- Size
- 8 mm
- Score
- No score line
- Form
- Tablet
- Manufacturer
- Direct_rx
- Drug class
- ACE inhibitor (blood pressure and heart medicine)
- NDC
- 72189-651, 43547-421, 72189-651-30
Source: the official drug label on DailyMed (US National Library of Medicine). Last checked .
Report a mistake
What is Lisinopril/Hctz used for?
Lisinopril/Hctz is used for high blood pressure and quitting smoking.
- Medicine type
- ACE inhibitor (blood pressure and heart medicine)
Official uses from the US prescribing label
Lisinopril and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril and hydrochlorothiazide.
Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).
Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.
Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.
Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.
These fixed-dose combinations are not indicated for initial therapy (see DOSAGE AND ADMINISTRATION).
In using lisinopril and hydrochlorothiazide tablets, consideration should be given to the fact that an angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril does not have a similar risk. (See WARNINGS.)
In considering use of lisinopril and hydrochlorothiazide tablets, it should be noted that Black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-Black. (See WARNINGS, Head and Neck Angioedema.)
From the FDA-approved label on DailyMed (published Dec 04, 2025).
Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.
Is this your pill? Check every detail
- One side shows H151 and the other side is plain.
- It is yellow, round, 8 mm.
- Its score line and coating match the details on this page.
- It came from a pharmacy package that names the same drug.
Ingredients
Active: Lisinopril, Hydrochlorothiazide
Inactive: Dibasic Calcium Phosphate Dihydrate, Magnesium Stearate, Mannitol, Ferric Oxide Yellow, Starch, Corn
Other pills with imprint H151
Same imprint, different listing. Check the color, size and maker against your pill.
Pills that look similar but are different drugs
Same color and shape, different medicine. This is why the imprint matters.
-
J 7
Prochlorperazine Maleate 10 mg
Yellow, round, 8 mm
Used for anxiety and schizophrenia
-
J 5
Prochlorperazine Maleate 5 mg
Yellow, round, 7 mm
Used for anxiety and schizophrenia
-
P100
Carbamazepine 100 mg
Yellow, round, 8 mm
Used for PTSD and bipolar disorder
-
APO F50
Fluvoxamine Maleate 50 mg
Yellow, round, 9 mm
Used for depression and panic disorder
-
497
Zolmitriptan 2.5 mg
Yellow, round, 7 mm
Used for migraine
-
254 G
Ropinirole 0.5 mg
Yellow, round, 8 mm
Used for Parkinson's disease